Any current/future new fundraising through debt or equity?

There are no immediate major capex plans or greenfield projects planned at this time. The company intends to consolidate and focus on backward integration of critical, high-volume products. No mention was made of any new fundraising through either debt or equity in the recent call. Current capacity utilization is around 50%-55%, and expansions or major investments will be considered only after optimizing existing capacity. Management did not indicate any plans for raising funds via debt or equity during the discussed period.

Any current/future capex/capital investment/strategic investment?

No immediate major capex or greenfield projects planned at present. Focus is on consolidating current operations and pursuing backward integration for critical, high-volume APIs. Plans for vertical integration are already underway for top five to six key products. Expansion of capacity, such as for Ibuprofen from current 700 metric tons to 1,200 metric tons per month, will only occur after reaching about 80-85% utilization of existing capacity. The company aims to improve operational efficiency and margins through R&D focused on cost and process improvements as well as backward integration. An

Future growth expectations in sales/revenue/volumes?

SMS Pharmaceuticals reported a strong Q1 FY24 with 110% year-on-year revenue growth, reaching INR 135 crores. The company expects 15%-20% revenue and profit growth for FY24 compared to FY23. Growth is driven by a robust API business, especially high-volume products like Ibuprofen, with capacity expandable from 700 MT to 1,200 MT/month once 80-85% utilization is achieved. The ARV segment is recovering with expected sustainable volumes in next few quarters. Diversification into anti-diabetic, anti-migraine, anti-ulcer, and anti-ED segments supports stability and growth. Focus on expanding regula

Future growth expectations in earnings/operating earnings/profits/EPS?

The company expects 15%-20% growth in both revenues and profits for FY24 compared to FY23. Operating margins are expected to be sustained at around 18%-19% going forward. Return on Capital Employed (ROCE) is anticipated to stabilize at 10%-12% for the full year FY24, with a target of reaching 15%-17% by the end of Q4 FY24. EBIT is expected to grow from the current quarterly INR19 crores to approximately INR80 crores to achieve the desired ROCE. The company is optimistic about sustaining growth driven by improved product mix, new product launches, and expansion in regulated markets. Ibuprofen v

SMS Pharmaceuticals LtdQ1 FY24Pharmaceuticals & Biotechnology

SMS Pharmaceuticals Ltd Q1 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹479P/E: 43.4Market Cap: ₹4.4K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

Order

N/A

Capex

0 of 4 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

SMS Pharmaceuticals reported a strong Q1 FY24 with 110% year-on-year revenue growth, reaching INR 135 crores.
The company expects 15%-20% revenue and profit growth for FY24 compared to FY23.
Growth is driven by a robust API business, especially high-volume products like Ibuprofen, with capacity expandable from 700 MT to 1,200 MT/month once 80-85% utilization is achieved.
The ARV segment is recovering with expected sustainable volumes in next few quarters.
Diversification into anti-diabetic, anti-migraine, anti-ulcer, and anti-ED segments supports stability and growth.
Focus on expanding regulated export markets where profitability is higher.
Long-term plan includes making Ibuprofen one of the largest globally.
Vertical integration for selected high-volume products is underway to improve margins.
No major capex planned currently; consolidation and backward integration are priorities.
New product launches and geographical expansion efforts are ongoing, with impact expected near fiscal year-end.

Margin guidance

Category 3

The company expects 15%-20% growth in both revenues and profits for FY24 compared to FY23.
Operating margins are expected to be sustained at around 18%-19% going forward.
Return on Capital Employed (ROCE) is anticipated to stabilize at 10%-12% for the full year FY24, with a target of reaching 15%-17% by the end of Q4 FY24.
EBIT is expected to grow from the current quarterly INR19 crores to approximately INR80 crores to achieve the desired ROCE.
The company is optimistic about sustaining growth driven by improved product mix, new product launches, and expansion in regulated markets.
Ibuprofen volumes and sales are expected to increase steadily, with a commercial launch phase expected by end FY24.
Growth in the ARV and anti-diabetic segments is expected to continue steadily, contributing to diversified revenue streams.

See what SMS Pharmaceuticals Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

There are no immediate major capex plans or greenfield projects planned at this time.
The company intends to consolidate and focus on backward integration of critical, high-volume products.
No mention was made of any new fundraising through either debt or equity in the recent call.
Current capacity utilization is around 50%-55%, and expansions or major investments will be considered only after optimizing existing capacity.
Management did not indicate any plans for raising funds via debt or equity during the discussed period.

Order book

The transcript does not explicitly provide specific details about the current or expected order book or pending orders of SMS Pharmaceuticals Limited. However, relevant insights related to business and demand include: - The ARV segment is witnessing a steady recovery with good volumes anticipated in the next few quarters, dependent on tenders won by partners. - Ibuprofen demand is increasing with capacity utilization around 50-55% and potential expansion planned upon reaching ~80-85% utilization. - Major products are expected to take off strongly by the end of Q4 FY24, contributing to improved returns. - The company anticipates sustained growth with 15%-20% top-line and bottom-line growth guidance for FY24. - No immediate major capex or greenfield projects are planned; focus is on consolidation and backward integration. No direct quantitative data on orderbook or pending orders is shared in the transcript.

See what SMS Pharmaceuticals Ltd management said on order book — free account, 30 seconds.

Capex plans

No immediate major capex or greenfield projects planned at present.
Focus is on consolidating current operations and pursuing backward integration for critical, high-volume APIs.
Plans for vertical integration are already underway for top five to six key products.
Expansion of capacity, such as for Ibuprofen from current 700 metric tons to 1,200 metric tons per month, will only occur after reaching about 80-85% utilization of existing capacity.
The company aims to improve operational efficiency and margins through R&D focused on cost and process improvements as well as backward integration.
Any major capex expansions are deferred until current capacities are optimally utilized.
The approach is cautious with emphasis on sustainable growth and maximizing in-house manufacturing capabilities rather than immediate large-scale investment.

Track SMS Pharmaceuticals Ltd — get its next earnings analysis in your feed

How does SMS Pharmaceuticals Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisSMS Pharmaceuticals Ltd

Rev 3Mar 3

See where SMS Pharmaceuticals Ltd sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does SMS Pharmaceuticals Ltd rank in Pharmaceuticals & Biotechnology?

Compare SMS Pharmaceuticals Ltd against every Pharmaceuticals & Biotechnology company (Q1 FY24) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What SMS Pharmaceuticals Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Aptus Pharma Ltd (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
Aptus Pharma Ltd (Q1 FY27)
Revenue from Operations for H2 FY26: ₹32.20 crore, up 117.5% YoY from ₹14.80 crore in H2 FY25 (Page 23) . Key concall takeaways from Aptus Pharma Ltd's Q1 FY27…
RPG Life Sciences Ltd (Q2 FY25)
Q2 FY25: ₹172.2 Crores . Key concall takeaways from RPG Life Sciences Ltd's Q2 FY25 earnings call — and how it ranks against sector peers.
FDC Ltd (Q3 FY23)
Q3FY23 Revenue from operations: ₹407 crores, up 19% YoY from ₹341 crores in Q3FY22 (Page 13). Key concall takeaways from FDC Ltd's Q3 FY23 earnings call — and…

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

SMS Pharmaceuticals Ltd Q1 FY24 Earnings Call Analysis

Revenue guidance

Fundraise plans

Capex plans

How does SMS Pharmaceuticals Ltd rank in Pharmaceuticals & Biotechnology?

Continue your research

What SMS Pharmaceuticals Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season